9 Meters Biopharma Inc

We strive to convert meaningful science into meaningful outcomes for patients, providers, and payors. by doing this, we believe we can also provide meaningful returns to our investors. 9 Meters is led by a strong management team and board of directors with a deep history of bringing novel GI therapeutics to public markets. The Board of Directors of 9 Meters Biopharma, Inc. sets high standards for the company’s employees, officers, and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines.

9 Meters initiated the VIBRANT study (VurolenatIde for short Bowel syndrome Regardless of pArenteral support requiremeNT), a placebo-controlled Phase 2 trial in SBS in Q2 2021., The study includes patients with all post-surgical types of SBS regardless of their parenteral support requirements.

Vurolenatide is patent-protected and has received Orphan Drug designation by the FDA.